Who are Human interferon α1b Inhalation Solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intron A, Peg-IFNα-2a, Pegylated interferon alpha 2, pegylated interferon a-2a, Peginterferon alfa 2 A, Peg-IFN α-2b combined with NAs.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/human-interferon-1b-inhalation-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Human interferon α1b Inhalation Solution — Competitive Intelligence Brief

Human interferon α1b Inhalation Solution (Human interferon α1b Inhalation Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alpha. Area: Immunology / Infectious Disease.

phase 3 Interferon alpha Interferon-alpha receptor (IFNAR) Immunology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Human interferon α1b Inhalation Solution (Human interferon α1b Inhalation Solution) — Kexing Biopharm Co., Ltd.. Human interferon α1b activates innate immune responses by binding to interferon-alpha receptors on immune and epithelial cells, enhancing antiviral and immunomodulatory activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Human interferon α1b Inhalation Solution TARGET	Human interferon α1b Inhalation Solution	Kexing Biopharm Co., Ltd.	phase 3	Interferon alpha	Interferon-alpha receptor (IFNAR)
Intron A	INTERFERON ALFA-2B	Merck & Co.	marketed	Interferon alpha		1986-01-01
Peg-IFNα-2a	Peg-IFNα-2a	Beijing 302 Hospital	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
Pegylated interferon alpha 2	Pegylated interferon alpha 2	Ain Shams University	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
pegylated interferon a-2a	pegylated interferon a-2a	Foundation for Liver Research	marketed	Interferon alpha	Interferon alpha receptor (IFNAR)
Peginterferon alfa 2 A	Peginterferon alfa 2 A	Dr. Conrado Fernandez	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
Peg-IFN α-2b combined with NAs	Peg-IFN α-2b combined with NAs	Shenzhen Third People's Hospital	marketed	Interferon alpha combined with nucleos(t)ide reverse transcriptase inhibitor	Interferon-alpha receptor (IFNAR); HBV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alpha class)

Dr. Conrado Fernandez · 2 drugs in this class
Ain Shams University · 1 drug in this class
Beijing 302 Hospital · 1 drug in this class
Foundation for Liver Research · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Kexing Biopharm Co., Ltd. · 1 drug in this class
Merck & Co. · 1 drug in this class
ANRS, Emerging Infectious Diseases · 1 drug in this class
Vertex Pharmaceuticals Incorporated · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Human interferon α1b Inhalation Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/human-interferon-1b-inhalation-solution. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab